ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO894

Results from GUIDAGE-CKD: Guideline-Compliant Care of Patients Aged 70+ with CKD

Session Information

  • Geriatric Nephrology
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Geriatric Nephrology

  • 1300 Geriatric Nephrology


  • Ebert, Natalie, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Schaeffner, Elke, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Fietz, Anne-Katrin, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Freitag, Julia, AOK Nordost - Die Gesundheitskasse, Berlin, Germany
  • Pöhlmann, Anna, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Mielke, Nina, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Bothe, Tim, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany

Currently, few data exist on guideline-based care for older patients with CKD. The GUIDAGE-CKD project develops quality indicators (QI) for outpatient care of pts 70+ years with CKD and tests them in Berlin Initiative Study (BIS) and claims data. We investigate trends over time after introduction of KDIGO guidelines in 2012.


Using a Delphi process, a set of 7 QIs was consented for use in claims data (Module 1). QIs were validated in BIS data with comprehensive claims data (Module 2). Prevalences of QIs were described in age- and sex-stratified random samples in claims data (n=62,200 indiv. 70+) for the years 2012, 2014, 2016, and 2018 and standardized to the German 70+ population. Trends over time were examined with Cochran-Armitage trend test (Module 3). Initial results using claims data were reported for 5 QIs.


Prevalence of CKD increased from 17.9% (95% confidence interval [CI] 15.0–21.4) in 2012 to 25.9% (CI 22.3–30.0) in 2018 (Table). Incidence of CKD increased from 6.3% (CI 4.5–8.8) in 2012 to 7.5% (CI 5.5–10.5) in 2018. The proportion of incident CKD cases with urinary albumin creatinine ratio (ACR) measurement (QI 8) increased from 10.9% (CI 10.0–12.0) in 2012 to 12.6% (CI 11.5–13.7) in 2018. The proportion of confirmed CKD G4-5 caseswith perscribed NSAIDs (QI 12, contraindicated) decreased from 3.8% (CI 2.9–4.9) in 2012 to 2.3% (CI 1.8–3.0) in 2018. The proportion of cases with CKD receiving combined prescriptions of ACE inhibitors (ACEi) and ARBs (angiotensin II receptor blockers) (QI 23, contraindicated) decreased from 3.0% (CI 2.6–3.3) in 2012 to 0.6% (CI 0.5–0.7) in 2018.


From 2012-2018, the prevalence and incidence of CKD increased constantly, while the proportion of contraindicated NSAID medications in stage 4-5 CKD and combined prescriptions of ACEi and ARBs decreased. These trends suggest improvements in CKD diagnosis, guideline adherence, and quality of care.